Deucravacitinib (TYK2 inhibitor) for PsA tx showed biomarker changes consistent with clinical improvement
⬇️IL-23, IL-17 and IFN-1 pathways vs. pbo
⬇️MMP3 (associated with joint damage), C4M
Abs#490
#ACR21
@RheumNow
https://t.co/mA1aHmtE5I https://t.co/BoAPKiMW9x
Links:
Biomarker Changes with Selective Tyrosine Kinase 2 Inhibitor, Deucravacitinib, …
https://bit.ly/3ESelX7
06-11-2021
